SCHEMBL2852899

SCHEMBL2852899

S=[C]Nc1ccc2ccccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.59
NPC1 O15118 9/20 0.46
RAB9A P51151 9/20 0.46
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPK1 P28482 1/20 0.43
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
NOS2 P35228 1/20 0.42
BACE1 P56817 1/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969950 0.80 NCF1 (0.59) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL5565908 0.80 NCF1 (0.59) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL4574516 0.80 NCF1 (0.59) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL10458402 0.76 NCF1 (0.71) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL30760998 0.76 NCF1 (0.71) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL5806618 0.74 NCF1 (0.68) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL5506476 0.74 NCF1 (1.00) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL6645329 0.72 NCF1 (0.65) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL22593292 0.72 NCF1 (0.65) NCF1NPC1RAB9AKMT2AKDM4E
SCHEMBL4937770 0.72 NCF1 (0.65) NCF1NPC1RAB9AKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786079-B2 Substituted nonadepsipeptides AICURIS GMBH & CO. KG. (DE) 2010-08-31 US disclosed
EP-1809653-B1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2010-01-20 EP disclosed
US-20080058251-A1 Substituted nonadepsipeptides BAYER HEALTHCARE AG (DE) 2008-03-06 US disclosed
EP-1809653-A1 SUBSTITUTED NONADEPSIPEPTIDES AiCuris GmbH & Co. KG (DE) 2007-07-25 EP disclosed
WO-2006042654-A1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO. KG (DE) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058251-A1 Substituted nonadepsipeptides VIP, DNPEP, LNPEP NCF1 368/4885NPC1 1181/4885RAB9A 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.